Cebix Incorporated

Creative Peptides Sweden Ab

Cebix Ab

La Jolla

John Wahren

James Callaway

Karin Ekberg

Bo-Lennart Johansson

Anders Carlsson

Michelle Mazzoni

Sheri Barrack

Joseph Bianchine

Howard Foyt

Hans J&ouml;rnvall

Mark Daniels

The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.

Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide

The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.

Sustained release preparation of pro-insulin C-peptide

Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Methods and kits for preventing hypoglycemia

The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.

Therapeutic applications for C-peptide

The present invention relates to the use of proinsulin C-peptide or a variant, derivative or fragment thereof in the manufacture of a medicament for reducing the OTc interval and the use of proinsulin C-peptide or a variant, derivative or fragment thereof in the manufacture of a medicament for reducing the risk of sudden death or 'dead in bed' syndrome; particularly in patients suffering from IDDM.

Reduction of the electrocardiographic QT interval

The invention features peptides that are fragments of the human insulin C-peptide, which peptides include the sequence ELGGGPGAG or a fragment thereof, or the sequence EGSLQ or a fragment thereof. The peptides have the ability to stimulate Na K ATPase activity. Also provided are biomimetic organic compounds exhibiting activation of Na K ATPase activity and/or cellular binding to renal tubule cells and fibroblasts. Such peptides and compounds are useful in combating diabetes and diabetic complications, or for stimulating Na K ATPase activity.

Growing community of inventors

Stockholm, Sweden

John Wahren